Introduction
Organ fibrosis is the common, irreversible endpoint of virtually all injuries to organs such as the liver, lung, kidney, and heart including but not limited to hepatic cirrhosis, chronic kidney disease (CKD), idiopathic pulmonary fibrosis (IPF), and chronic heart failure. Fibrosis is defined as the formation of fibrous connective tissue in response to injury. After acute injury, fibrosis might often be required to maintain tissue structure and assist in tissue repair. However, continuous activation of fibrotic processes can lead to overwhelming pathologic extracellular matrix (ECM) deposition, a destructive process that progresses independent of the initial injury, destroying tissue architecture and ultimately leading to an irreversible loss of organ function. Therefore, targeting fibrosis might be an important therapeutic strategy in many chronic diseases.
Fibrotic diseases such as chronic kidney disease and liver cirrhosis are increasing and are considered major causes of morbidity and mortality [1, 2] . However, specific therapeutic options to inhibit or reverse fibrosis are still lacking, making the development of new therapeutic targets of utmost importance.
One of the key characteristics of fibrosis is the reactivation of quiescent developmental signaling pathways, which drive myofibroblast proliferation and differentiation and ECM production. Although transient activation may be necessary to initiate tissue repair, sustained activation of these developmental pathways is thought to lead to pathologic pericyte/ fibroblast activation, myofibroblast transdifferentiation, and ECM production. In this review, we will discuss the role of three major developmental signaling pathways involved in fibrosis: Hedgehog, Notch, and Wnt signaling. Our intent is to give a short, but comprehensive summary on the vast array of the most recent findings.
This article is part of the Topical Collection on Activated Myofibroblasts and Fibrosis in Various Organs
Hedgehog Signaling Hedgehog (Hh) signaling is an important developmental signaling pathway, which is reactivated in diseases such as cancer and fibrosis. It can be divided into canonical and noncanonical Hedgehog signaling. Canonical Hedgehog signaling ( Fig. 1) is initiated by the binding of one of three Hedgehog homologs-Desert Hedgehog homolog (Dhh), Indian Hedgehog homolog (Ihh), or Sonic Hedgehog homolog (Shh) to the transmembrane protein patched (Ptc1). In the absence of ligand binding, Ptc1 suppresses the translocation of smoothened (Smo), a G protein-coupled transmembrane receptor, to the primary cilium. Inactive Smo allows binding of the negative regulator suppressor of fused (SUFU) to Gli proteins and cleavage of Gli to a Gli repressor form. Upon Hh binding, Ptc1 releases its inhibition on Smo, resulting in an accumulation and activation of Smo at the primary cilium. Activated Smo inhibits binding of SUFU to Gli. Gli proteins subsequently accumulate and translocate to the nucleus where they induce transcription of Hedgehog target genes.
Three different Gli proteins-Gli1, Gli2, and Gli3-mediate Hedgehog signaling in vertebrates. All three proteins possess a C2H2 zinc finger DNA binding domain, as well as an activator domain at the C-terminus (Gli A ), while both Gli2 and Gli3 have an additional N-terminal repressor domain (Gli R ). Recent research suggests that Gli2 acts as the major activator of Hedgehog signaling, whereas Gli3 inhibits Hedgehog signaling and Gli1 augments downstream Gli2 signaling. Non-canonical Hh signaling comprises Ptc1 signaling independent of Smo regulation, Smo signaling independent of Gli protein regulation, and Gli protein activation independent of Smo [3, 4] .
Recent evidence indicates that Hedgehog signaling is one of the key developmental signaling pathways that mediate organ fibrosis in several organs such as the kidney, lungs, and liver.
After kidney injury, several groups reported that tubular epithelial cells (TECs) upregulate the expression of Hh ligands Shh and Ihh leading to an increased interstitial expression of Gli1 and Gli2 in pericytes and/or fibroblasts [5] [6] [7] . Consistent with this, Zhou et al. observed strong tubular expression of Shh in kidney biopsies of CKD patients [7] . In in vitro models, Shh triggered proliferation, matrix production, and myofibroblast differentiation, while inhibition of Hedgehog signaling via Smo inhibition ameliorated these effects [5] [6] [7] [8] . Further in support of a profibrotic role for Hh signaling, in vivo Shh hydrodynamic gene transfer increased proliferation and worsened kidney fibrosis after ischemia reperfusion injury (IRI) [7] . However, suppression of canonical Hh signaling in vivo showed conflicting results. On the one hand, KO of Gli1 in a unilateral ureteral obstruction (UUO) mouse model attenuated kidney fibrosis [5] and canonical Hh inhibition with the Smo antagonist cyclopamine reduced kidney fibrosis [5, 7] . On the other hand, Fabian et al. did not observe reduced fibrosis after Smo inhibition using the cyclopamine derivate IPI-926 with increased serum half-life and potency [6] . In accordance with these findings, we observed that conditional KO of Gli2 in myofibroblast precursors ameliorated kidney fibrosis, whereas a full KO of Gli1 did not have any effect [9••] . The reason for this discrepancy is unclear but might be explained by different mouse strains. Interestingly, Rauhauser et al. recently reported that conditional KO of the Hedgehog activator Smo in NG2 + pericytes reduced F4/80 + macrophage infiltration, increased tubular proliferation, and apoptosis following UUO but did not change interstitial kidney fibrosis [10] .
Our recent data suggests that Gli proteins are critical drivers of myofibroblast cell cycle progression in kidney fibrosis. Retroviral overexpression of Gli2 dramatically increased proliferation in the pericyte-like cell line 10T1/2 while RNAi against Gli2 resulted in a G0/G1 cell cycle arrest. Conditional knockout of Gli2 in myofibroblast precursors induced a cell cycle arrest with subsequently reduced fibrosis in the UUO mouse model of kidney fibrosis. Importantly, pharmacologic inhibition of Gli2 with darinaparsin or GANT61 reduced fibrosis via a cell cycle arrest of myofibroblasts and even improved kidney function after IRI [9••] .
In lung fibrosis models and samples from patients with IPF, it has been reported that after injury, Shh is upregulated in epithelial cells, whereas Ptc1, Smo, Gli1, and Gli2 are upregulated in interstitial myofibroblasts and/or inflammatory cells (macrophages and lymphocytes) [11] [12] [13] . Additionally, Cigna et al. observed a decrease of the negative regulators Gli3 and PTC in fibrotic lesions [12] . Shh stimulation of a human fibroblast cell line (CCD25-Lu) increased proliferation, migration, and matrix production, while inhibition of canonical Hh signaling using the Smo antagonist cyclopamine reduced these effects [11] . In vivo conditional KO of Smo in collagen I-expressing cells ameliorated bleomycin-induced lung fibrosis as measured by α-SMA and collagen I expression [14] . Moreover, inhibition of Gli activity using HPI-4 or GANT61 blocked transforming growth factor beta 1-induced myofibroblast differentiation in vitro [12] . Similar to the kidney, there is also conflicting data in lung fibrosis, suggesting that inhibition of canonical Hh signaling by Smo inhibition might be less effective compared to directly targeting Gli. Moshai et al. reported that directly targeting Gli by GANT61, but not inhibition of Smo with GDC-0449 attenuated bleomycin-induced lung fibrosis [15] . The antifibrotic effect of GANT61 on lung fibrosis has recently been confirmed by Liang et al. [16] . Interestingly, similar to what has been reported in the cancer literature, the authors report a direct activation of Gli2 by transforming growth factor beta signaling, which might explain why directly targeting Gli is more effective compared to Smo inhibition. Furthermore, the authors also report an effect of GANT61 on fibrosis in a mouse model of systemic sclerosis.
Liver cirrhosis is an endpoint of virtually all chronic liver injuries including but not limited to non-alcoholic steatohepatitis (NASH), viral hepatitis, and alcohol-induced liver damage (ALD). Hedgehog signaling correlates with severity of liver fibrosis in chronic liver diseases as nonalcoholic fatty liver disease (NAFLD), ALD, and hepatitis B or C, in both humans and mice [17] [18] [19] [20] . Similar to reports in kidney and lung injury, epithelial cells, i.e., hepatocytes, secrete Hedgehog ligands after injury [21] . In vitro, these Hh ligands stimulate myofibroblast differentiation and viability of hepatic stellate cells while inhibition of Hedgehog signaling by cyclopamine or Shh-neutralizing antibodies ameliorated these effects [20, 22, 23] . In vivo, Michelotti et al. reported that KO of canonical Hh signaling by conditional KO of Smo in α-SMA+ cells reduced liver fibrosis [24] . Similarly, inhibition of Smo using the small molecule inhibitor cyclopamine decreased liver fibrosis and hepatocarcinogenesis in Mdr2 KO mice and either cyclopamine or GDC-0449 attenuated liver fibrosis after bile duct ligation [25, 26] . Vice versa, increased Hedgehog signaling via (a) Ptc haploinsufficiency (Ptc(+/−) mice) [20] or (b) hydrodynamic gene transfer of Shh aggravated liver fibrosis [27•] .
In the heart, it has been reported that Hh signaling is upregulated in mouse models of ischemic cardiac injury [28, 29] . However, there is contrary data on the role of Hh signaling in cardiac fibrosis. Kusano et al. reported that a Shh gene transfer attenuates fibrosis, promotes neovascularization, and augments ventricular function in mouse models of myocardial infarction and chronic myocardial ischemia [29] . Similarly, injection of either Shh-overexpressing mesenchymal stem cells or Shh-overexpressing CD34 + cells preserved ventricular function, reduced infarct size, and improved angiogenesis after myocardial infarction [30, 31] . Moreover, injection of recombinant Shh decreased infarct size and arrhythmias after cardiac IRI [32] . In contrast, inhibition of endogenous Hh signaling by cyclopamine improved both cardiac fibrosis and ventricular function after IRI [28] . We demonstrated that independent of Hh signaling, ablation of Gli1 + cells reduced interstitial myocardial fibrosis and improved left ventricular function after ascending aortic constriction [33••]. In summary, current studies indicate that, while endogenous Hh worsens cardiac fibrosis, strong exogenous overexpression of Hh may improve angiogenesis and fibrosis. Overexpression of Shh might primarily reduce fibrosis by attraction of endothelial progenitor cells and enhanced angiogenesis resulting in reduced tissue hypoxia after injury. In our opinion, these conflicting reports reflect the highly cell-and time pointdependent role of Hedgehog signaling. Further studies are needed to dissect both profibrotic and antifibrotic roles of Hh signaling in different cell types after cardiac injury.
Gli1 Marks Resident Perivascular Mesenchymal Stem Cell Like Myofibroblast Progenitors
Apart from Hh being a central mediator of fibrosis, we have recently identified Gli1-expressing cells as critical perivascular myofibroblast progenitors across major organs including the heart, kidney, lung, and liver. We observed that Gli1-expressing cells reside in the perivascular niche across organs and represent a minor subfraction of the plateletderived growth factor receptor beta stromal population. We could demonstrate that these perivascular Gli1-expressing cells fulfill all criteria that have been described for mesenchymal stem cell (MSC) including surface pattern, trilineage differentiation capacity, and increased colony-forming unit capacity. Importantly, others have also described Gli1 + cells as MSC-like cells in both the mouse incisor and suture of craniofacial bones [34, 35] . Using the state-of-the-art inducible genetic fate tracing in bigenic Gli1CreER;tdTomato mice, we could demonstrate that Gli1 + cells tremendously expand after injury and become fibrosis driving myofibroblasts in the kidney, heart, liver, and lung. Importantly, ablation of Gli1 + cells reduced fibrosis and preserved organ function, indicating reduction of fibrosis as a potential therapeutic target [33••].
Notch Signaling
Notch signaling (Fig. 1) is a highly conserved pathway regulating cell-cell communication during embryogenesis that is reactivated during fibrosis. In mammals, Notch signaling is induced by the single-pass transmembrane protein ligand families Delta-like or Jagged. Binding of the ligands to the Notch receptor family (Notch1-4) initiates cleavage of the receptor by TACE (TNF-α ADAM metalloprotease-converting enzyme), which releases the Notch extracellular domain (NECD). A second cleavage by γ-secretase releases the Notch intracellular domain (NICD), allowing nuclear translocation and activation of Notch target genes. Similar to other developmental pathways, Notch signaling is usually suppressed in adult tissue and reactivated during fibrosis, where it induces Notch target genes, including the hairy and enhancer of split (Hes1-7) and hairy/enhancer-of-split related with YRPW motif family.
In the kidney, increased cleaved Notch1 expression has been reported in tubular-epithelial and interstitial cells following folic acid-induced kidney injury in mice as well as tubularepithelial cells of human CKD samples [36] . Furthermore, cleaved Notch1, Notch2, and Jagged1 expression in podocytes correlates with proteinuria, while tubulointerstitial cleaved Notch1 expression correlates with tubulointerstitial fibrosis and renal dysfunction of various nephropathies [37] . In accordance, overexpression of cleaved Notch1 in tubular-epithelial cells caused severe kidney fibrosis [36] and conditional overexpression of the Notch1 intracellular domain in proximal tubular-epithelial cells aggravated kidney fibrosis following IRI [38] . Conversely, KO of Notch3 reduced kidney fibrosis after UUO [39] and conditional KO of the central transcriptional regulator of Notch signaling RBP-J in tubular-epithelial cells ameliorated fibrosis following folic acid-induced kidney injury [36] . Pharmacological inhibition of Notch signaling using a γ-secretase inhibitor (GSI) attenuated tubular damage and kidney fibrosis in various kidney injury models including IRI, UUO, or folic acid-induced kidney injury [36, 38, 40, 41] . In vitro data suggests that Notch signaling stimulates fibroblast proliferation [39, 41] . In conclusion, several studies suggest that after kidney injury, increased tubular-epithelial Notch1 and Notch3 signaling drive fibrosis by inducing proliferation of epithelial cells and interstitial cells which include myofibroblasts.
In mouse models of lung fibrosis, data suggests a signaling axis from pulmonary capillary endothelial cells (PCECs) to interstitial myofibroblasts. After lung injury, Jagged1 expression was increased on PCECs with subsequent upregulation of Increased Notch signaling has been reported in liver fibrogenesis by several studies [49, 50] . The Notch ligand Jagged1 has been reported to be primarily upregulated in neovessels and bile ductules in fibrotic liver tissue, while the Delta-like ligand 4 (Dll4) shows increased expression in liver sinusoidal endothelial cells and Kupffer cells of patients with liver fibrosis [51, 52] . In CCL4-induced liver fibrosis, Notch3 and Hes expression was increased in hepatic stellate cells (HSCs), whereas Jagged1 expression was increased in hepatocytes [53] . Inhibition of Notch signaling using a GSI (DAPT or avagacestat) reduced fibrosis, myofibroblast transformation, and proliferation (one study) in several animal models of liver fibrosis, including CCL4-induced liver fibrosis and bile duct ligation [53] [54] [55] . Additionally, KO of RBP-J in myeloid cells reduced both inflammatory cell infiltration and fibrosis [56] . In contrast, recombinant Dll4 protein reduced fibrosis and inflammation in CCL4-induced hepatic fibrosis, but led to massive hepatic necrosis after bile duct ligation by regulating CCL2 expression via NF-κB [52] . In vitro, Hes1 induced downstream Notch target genes α-SMA and Col1a2, while inhibition of Notch signaling attenuated myofibroblast transformation [54, 57] . In summary, the recent literature on Notch signaling in liver fibrosis suggests activation of Notch signaling by increased Jagged1 expression in neovessels and bile ductules leading to activation and myofibroblast transdifferentiation of responding HSCs.
The role of Notch signaling in mediating fibrosis has been confirmed in other diseases as well. Notch signaling was increased in skin lesions of patients with systemic sclerosis, and inhibition of Notch signaling using a GSI or antisense construct attenuated bleomycin-induced dermal fibrosis [58, 59] . In spinal cord injury, KO of myeloid RBP-J, but not universal Notch inhibition, inhibited fibrosis and accelerated recovery [60] . In most fibrosis models, Notch signaling appears to mediate profibrotic effects after injury. Surprisingly, in cardiac fibrosis models, Notch signaling has been reported to conserve cardiac function. Transgenic overexpression of Jagged1 in mice decreased cardiomyocyte hypertrophy and fibrosis after pressure overload, and intramyocardial injection of Jagged1 improved myocardial function after MI [61, 62] . Further, Jagged1 hydrogels preserved cardiac output and stroke output, while reducing cardiac fibrosis in a rat MI model [63] . Vice versa, inhibition of Notch1 by small interfering RNA (siRNA) increased myocardial infarction size and worsened cardiac function [62] .
Wnt Signaling
Canonical Wnt signaling (Fig. 1) is initiated by binding of one of the 19 secreted glycoprotein Wnt ligands to Frizzled receptors and the co-receptors LRP5/6. The Wnt-Frizzled-LRP5/6 complex then activates disheveled, which initiates the inactivation of the destruction complex consisting of APC, axin, GSK-3β, PP2a, and CK1α. In the absence of Wnt ligands, the destruction complex phosphorylates β-catenin, which is subsequently ubiquitinated and degraded. In the presence of ligands, LRP5/6 binds to axin, followed by dissociation of GSK-3β and inactivation of the destruction complex. As a consequence, β-catenin accumulates and translocates to the nucleus, where it induces Wnt target gene expression.
In kidney fibrosis upregulation of Wnt ligands and Wnt pathway members has been reported in both murine kidney injury models [64, 65, 66 •] and human samples [67, 68] . Several studies have provided in vivo evidence that Wnt signaling mediates fibrosis after injury. Constitutive activation of β-catenin in interstitial pericytes was sufficient to induce spontaneous myofibroblast differentiation [69] and overexpression of Wnt1 5 days after IRI-aggravated CKD [66•] . Similarly, KO of the Wnt antagonists secreted Frizzledrelated protein 1 (sFRP1) or dapper3 made mice more prone to fibrosis after UUO [70, 71] . Aberrant Wnt signaling has also been reported to mediate glomerulosclerosis: hydrodynamic gene transfer of Wnt1 or induction of β-catenin by intravenous LiCl injection increased albuminuria and suppressed expression of differentiation markers, while inhibition of Wnt signaling using dickkopf1 (Wnt inhibitor) or a podocyte-specific β-catenin KO ameliorated podocyte injury [67, 72] . Suppression of Wnt signaling using ICG-001, a small molecule inhibitor of the interaction between transcriptional co-activator CREP binding protein and β-catenin, decreased renal renin-angiotensin system (RAS) activity in adriamycin-induced nephropathy [73] . Moreover, ICG-001 treatment also reduced proteinuria, and fibrosis in adriamycin induced nephropathy [73] . Maarouf Similar to the kidney, increased Wnt signaling has been reported to drive pulmonary fibrosis. β-Catenin was increased in lungs from IPF patients and in pulmonary lesions of patients with systemic sclerosis [76] [77] [78] . Furthermore, Wnt10a expression correlated with mortality and acute exacerbations, while expression of LRP5 and LRP6 in peripheral monocytes correlated with disease severity of IPF patients [79, 80] . The critical role of Wnt signaling in promoting pulmonary fibrosis has been further supported by in vivo data from rodent models. KO of the Wnt co-receptor LRP5 decreased bleomycin-induced pulmonary fibrosis [79] . In accordance, inhibition of Wnt signaling using ICG-001 ameliorated bleomycin-induced lung fibrosis [81] . The enzymes tankyrase 1 and 2 mediate the degradation of the destruction complex protein axin and therefore increase β-catenin signaling [82] . Inhibition of tankyrase 1 and 2 using the small molecule inhibitor XAV939 and subsequent inhibition of β-catenin signaling attenuated bleomycin-induced lung fibrosis in vivo [83] [84] [85] . NSC668036, a small molecule inhibitor of disheveled, reduced bleomycin-induced lung fibrosis in vivo and reduced proliferation and migration of fibroblasts in vitro [86] . In summary, it has been shown that epithelial and endothelial cells as well as fibroblasts upregulate Wnt ligands such as Wnt5a and Wnt10a following bleomycin-induced lung injury [80, 87] . Downstream activation of the Wnt pathway has been reported in both epithelial cells and fibroblasts [76, 77] . In vitro, Wnt signaling induced mesenchymal differentiation, proliferation, and migration of fibroblasts [77] .
Increased β-catenin expression has also been reported in patients with hepatic fibrosis, and polymorphisms in the Wnt pathway are associated with liver fibrogenesis and inflammation in chronic HCV patients [88, 89] . Increased expression of Frizzled2, Wnt4, and Wnt5 has been reported in activated HSC in vitro [90] . However, despite upregulation of Wnt4, Wnt5, and Fzd2, activation of rat HSC did not alter β-catenin phosphorylation or nuclear translocation, suggesting the presence of non-canonical Wnt signaling during liver fibrosis [90] . In accordance, Wnt5a reduced HSC apoptosis and increased expression of profibrotic markers via non-canonical Wnt signaling in Kupffer cells in vitro [91] . Various groups reported a role of canonical Wnt signaling in liver fibrogenesis with increased β-catenin expression in activated HSC following injury [89, 92] . Inhibition of β-catenin signaling by siRNA reduced proliferation and collagen production in HSC in vitro [89] . In various animal models of hepatic fibrosis, Wnt antagonism via ICG-001, Dickkopf1, or Delta-like 1 homolog antibodies all attenuated liver fibrosis [92] [93] [94] . Additionally, KO of the Wnt inhibitor sFRP5 significantly enhanced CCL4-induced liver fibrosis [95] . In summary, various groups have demonstrated a significant profibrotic role of Wnt signaling in the liver, where Wnt ligands, in particular Wnt5a, activate HSC to become fibrosis driving myofibroblasts. However, further research is needed to determine the exact canonical and/or non-canonical mechanisms.
During cardiac fibrosis, increased Wnt signaling has been reported in (Sca+/CD31−) progenitor cells, endothelial cells, and/or perivascular α-SMA + cells in myocardial infarction models [96, 97] . Patients with ischemic dilated cardiomyopathy had increased expression of the Wnt target gene-Wnt1-inducible signaling pathway protein 1 (Wisp-1)-and decreased sFRP1 expression, while β-catenin accumulated in epicardial fibroblasts from explanted failed pediatric heart allografts [98, 99] . Interestingly, there are conflicting reports on the effect of Wnt signaling on cardiac fibrosis and repair in mouse models. On the one hand, it has been reported that fibroblast-specific β-catenin KO decreased fibroblast expansion but impaired cardiac function after ischemia reperfusion injury [100] . Moreover, overexpression of Wnt10b in cardiomyocytes decreased fibrosis and improved cardiac function and angiogenesis after myocardial infarction [101] . On the other hand, Laeremans et al. reported that inhibition of Frizzled increased angiogenesis, reduced infarct size expansion, and improved cardiac function after MI [102] .
Several groups have also focused on the role of the Wnt inhibitors-secreted Frizzled-related protein 1 and 2 (sFRP1 and sFRP2) in cardiac repair. Loss of sFRP1 increased Wnt signaling and induced cardiac fibrosis, ventricular dilation, and hypertrophy in aging mice [98] . Vice versa, overexpression of sFRP1 augmented cardiac function after MI, while reducing scar size [103] . Kobayashi et al. showed that sFRP2 activated procollagen C proteinase, which cleaves procollagen to mature ECM components [104] . KO of sFRP2 reduced mature collagen content and fibrosis, while preserving cardiac function after infarction [104] . In contrast, He et al. reported that exogenous administration of sFRP2 reduces collagen deposition and left ventricular fibrosis after MI [105] . Further, KO of the negative Wnt regulator Kruppel-like factor 15 worsened cardiac function and promoted endothelial differentiation of cardiac progenitor cells (Sca1+ or cKit+) [106] . In a recent study, sFRP2 treatment and subsequent Wnt6 inhibition promoted cardiac differentiation of Sca1+/cKit+ CPC after IRI [107] . To summarize, various reports show a profibrotic role of Wnt signaling in the heart while others show a proregenerative role. This might be explained by a highly cell and context-dependent role of Wnt signaling at different stages during cardiac injury and repair. Similar to the Hh signaling pathway, Wnt signaling in some cell types (e.g., cardiomyocytes) might aid in the cardiac regeneration process while strong evidence suggests a profibrotic role of Wnt signaling in cardiac myofibroblasts. Further studies are needed to dissect the cell-specific role of Wnt signaling in cardiac injury and repair and to untangle the complex interaction with other pathways where a co-activation might be critical for a proregenerative versus profibrotic effect of the Wnt pathway.
Crosstalk of Hedgehog, Wnt and Notch signaling
As all three here-described developmental signaling pathways are activated by similar stimuli and can promote similar profibrotic changes, crosstalk in between these pathways seems likely. Although only few studies reported direct evidence of Wnt, Notch, and Hh interaction in models of fibrosis, crosstalk has indeed been reported in other biological settings. In progenitor cells, Notch and Wnt have been reported to be mutually antagonistic: Kwon et al. reported that Notch reduces Wnt signaling by inhibiting accumulation of phosphorylated β-catenin in embryonic stem cells [108] . Furthermore, upregulation of Notch and subsequent downregulation of Wnt promoted differentiation of Nkx2.5 + or Isl1 + cardiac progenitor cells [109] . Vice versa, Wnt agonists attenuated Notch signaling in a zebrafish model of liver fibrosis and attenuation of Notch signaling led to increased differentiation and proliferation of Notch-responsive Tp1 + hepatic progenitor cells [110] . Synergistic crosstalk has been reported between Wnt and Hh signaling: Gli1 induced Wnt2b, Wnt4, and Wnt7b expression as well as canonical Wnt signaling, while Gli3R antagonized not only Hh signaling but also active β-catenin [111, 112] . In return, β-catenin signaling antagonized Gli3R and induced Gli1 expression via c-myc [113] . Moreover, β-catenin stabilized Gli1 mRNA via the RNA-binding protein-coding region determinant-binding protein (CRD-BP) [113] .
The interaction between Notch and Hh signaling has been reported as well: both Dhh and Shh induced the Notch target gene Hes1 in C3H/10T1/2 pericyte like cells, while Notch signaling increased Shh expression in neural stem cells, suggesting mutual synergism of the two pathways [114, 115] . Additionally, transgenic Gli1 expression induced both Jagged1 and Notch1 expression in murine brains [116] .
These reports indicate that the three developmental signaling pathways-Wnt, Notch, and Hh-closely interact to regulate proliferation and determine cell fate. While both Hh/Notch and Hh/Wnt interactions may promote mutual synergism, the Wnt/ Notch interaction can antagonize each other to regulate cell fate and differentiation. A better understanding of crosstalk between the pathways might allow for more nuanced approaches to reduce fibrosis by specifically modulating proliferation and differentiation of myofibroblasts and their progenitors.
Conclusions
Fibrosis is an immensely complex process that involves activation, reactivation, and crosstalk of various pathways. A common fibrotic theme across all major organs is the reactivation of the developmental signaling pathways Wnt, Notch, and Hh after organ injury. Usually quiescent in adult tissues, reactivation of these pathways initiates tissue repair by increasing proliferation and inhibiting apoptosis, therefore aiding in organ injury repair. However, persistent activation induces uncontrolled proliferation, myofibroblast transformation, and ECM production resulting in a loss of organ function.
Although extensive research has been done in the last years on the role of developmental signaling pathways in fibrosis, we still lack knowledge about their interplay and their contextdependent tight regulation in different cell types. Single gene KO studies have elucidated spotlight-like small parts of an extremely intricate signaling cascade, yet the complex interplay between signaling cascades and in-between different cell types still remains largely unknown. The recent discovery of the CRISPR/Cas9 system to perform multiplex gene editing will allow for simultaneous knockout experiments of critical pathway members within one and across different pathways and will therefore help to untangle the complex role of developmental signaling pathways is organ fibrosis. 
